AIM
RMD icon

Acrospire Investment Management’s ResMed RMD Stock Holding History

Acrospire Investment Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-400
Closed -$31K – 1138
2017
Q2 		$31K Buy
+400
New +$28.6K 0.03% 1259
2016
Q4 		– Sell
-1,400
Closed -$91K – 2390
2016
Q3 		$91K Buy
1,400
+200
+17% +$13.3K 0.06% 634
2016
Q2 		$76K Sell
1,200
-400
-25% -$23.6K 0.06% 722
2016
Q1 		$93K Buy
+1,600
New +$90.6K 0.06% 375

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acrospire Investment Management's RMD Position: Q3 2017 in Review

Acrospire Investment Management sold out of ResMed (RMD) in Q3 2017, closing a stake of 400 shares — an estimated $31K sold.

Acrospire Investment Management first reported a position in RMD in Q1 2016 and held it in 4 quarters. The position peaked at $93K in Q1 2016. 362 funds tracked by Wall St. Rank hold RMD as of Q3 2017.

  • Acrospire Investment Management reported no remaining ResMed position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 400 ResMed shares in Q3 2017, an estimated $31K.
  • Acrospire Investment Management first reported a position in ResMed in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's ResMed position peaked at $93K in Q1 2016.
  • 362 funds tracked by Wall St. Rank held ResMed as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.